## (19) World Intellectual Property Organization International Bureau



## 

(43) International Publication Date 16 June 2005 (16.06.2005)

## (10) International Publication Number WO 2005/053709 A3

- (51) International Patent Classification': A61K 31/663, 31/337, 31/4196, A61P 35/00
- (21) International Application Number:

PCT/EP2004/0 13728

(22) International Filing Date:

2 December 2004 (02.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0328040.1

3 December 2003 (03.12.2003)

- (71) Applicant: UNIVERSITY OF SHEFFIELD [GB/GB]: Firth Courth, Western Bank, Sheffield SIO 2TN (GB).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD. MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Firth Courth, Western Bank, Sheffield SIO 21N (GB).

(72) Inventors; and

(75) Inventors; Applicants (for US only): COLEMAN, Robert, Edward [GB/GB]; 8 Carsick View Road, Fulwood, Sheffield SIO 31Z (GB). HOLEN, Ingunn [NO/GB]; 140 Langsett Road South, Oughtibridge, Sheffield S35 OHA (GB). NEVILLE-WEBBE, Helen [GB/GB]; 42 Abbeydale Park Rise, Dore, Sheffield S17 3PD (GB).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(74) Title: PHARMACEUTICAL USES OF BISPHOSPHONATES

(57) Abstract: A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a chemotherapeutica agent selected from the group consisting of: taxol, a derivative thereof and letrozole, followed sequentially by a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate. The invention further provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate followed sequentially by a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate. The invention further provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate. The invention further provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate. The invention further provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate. The invention further provides are method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate. The invention further provides are a ca sequentially by an effective amount of a bisphosphonate. The invention further provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate followed sequentially by an effective amount of TRAIL.